BioCardia Files 8-K Report

TL;DR

BioCardia filed an 8-K, mostly standard disclosures, no major news yet.

AI Summary

On March 4, 2024, BioCardia, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a regulatory disclosure. No specific financial figures or material events were detailed in the provided excerpt, but it confirms the company's ongoing reporting obligations.

Why It Matters

This filing confirms BioCardia's compliance with SEC reporting requirements, providing transparency to investors about the company's status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• 320 Soquel Way (location) — Business Address
• Sunnyvale (location) — City
• CA (location) — State
• 94085 (location) — ZIP Code
• 650-226-0123 (phone_number) — Business Phone
• Tiger X Medical, Inc. (company) — Former Company Name
• Cardo Medical, Inc. (company) — Former Company Name
• CLICKNSETTLE COM INC (company) — Former Company Name

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant

Filing Documents

• bcda20240303_8k.htm (8-K) — 27KB
• ex_633988.htm (EX-99.1) — 20KB
• 0001437749-24-006362.txt ( ) — 198KB
• bcda-20240304.xsd (EX-101.SCH) — 4KB
• bcda-20240304_def.xml (EX-101.DEF) — 13KB
• bcda-20240304_lab.xml (EX-101.LAB) — 17KB
• bcda-20240304_pre.xml (EX-101.PRE) — 13KB
• bcda20240303_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 4, 2024, BioCardia, Inc. (the "Company") issued a press release announcing positive interim results from the Phase III randomized controlled trial of its CardiAMP autologous cell therapy in 110 randomized patients with advanced chronic heart failure at mean 20-month follow-up. Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. The data was presented today by Amish Raval, MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics 2024 annual meeting. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated March 4, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: March 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR